Yana Najjar, MD
Hematology-Oncology · Washington, DCNPI 1003112434
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Immunocore Limited at 45.7% of the total. 2025 is the largest year on record at $43,985, more than ten times the $186 reported in 2019.
Across 163 payments — averaging $818.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Immunocore Limited$61K
- Merck$30K
- Array Biopharma Inc$14K
- Pfizer$12K
- Mallinckrodt Hospital Products Inc.$8K
- E.r. Squibb & Sons, L.L.C.$6K
- plus $2K from 6 others
Across 161 payments — averaging $59,006 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$5.4M
- Pfizer$3.4M
- E.r. Squibb & Sons, L.L.C.$281K
- Day One Biopharmaceuticals$140K
- Array Biopharma Inc$118K
- Takeda Pharmaceuticals U.S.A., Inc.$70K
- plus $97K from 4 others
What the payments were for
- Consulting fees$59,48645%
- Speaking & faculty fees$59,89045%
- Travel & lodging$11,1238%
- Food & beverage$2,9172%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Immunocore Limited | 90 | $61,028 |
| Merck | 29 | $29,530 |
| Array Biopharma Inc | 21 | $14,076 |
| Pfizer | 7 | $12,453 |
| Mallinckrodt Hospital Products Inc. | 2 | $7,930 |
| E.r. Squibb & Sons, L.L.C. | 7 | $5,981 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $2,053 |
| Delcath Systems | 1 | $125 |
| Amgen | 1 | $101 |
| Regeneron Healthcare Solutions, Inc. | 1 | $73 |
| Exelixis Inc. | 1 | $44 |
| Novartis | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hematology-oncology providers in District of Columbiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology-oncology in Washington
- Antoine FinianosWashington$2K
- Patricia OnealWashington$0
- Sunil AdigeWashington$0
- Chukwuemeka IhemelanduWashington$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.